A 68-year-old man on tirzepatide lost 28.7 pounds total, but 34% of that weight loss was muscle — with muscle and body weight both dropping about 15% proportionally.
34% muscleMore than a third of the total weight lost on tirzepatide came from skeletal muscle rather than fat in this case study
What the researchers found
A 68-year-old male with BMI 31.2 and HbA1c 5.9% was treated with tirzepatide. Results:
- Total weight loss: 28.7 lbs (BMI dropped from 31.2 to 26.8)
- Skeletal muscle mass loss: 9.9 lbs (34% of total weight loss)
- Both body weight and muscle mass decreased by approximately 15% from baseline
- HbA1c normalized from 5.9% to 5.3%
The proportional nature of the muscle loss — roughly matching the percentage of total weight lost — suggests muscle wasn't being disproportionately targeted. However, losing a third of all weight as muscle is still clinically significant, particularly in an older patient at risk for sarcopenia.
Why it matters
Muscle loss during rapid weight loss — sometimes called 'Ozempic muscle' — is a major clinical concern, especially for older adults who are already at risk of sarcopenia and frailty. While large tirzepatide trials report muscle loss, this is reportedly the first published case with multiple serial body composition measurements, providing a detailed time course of exactly when and how much muscle is lost. The finding that muscle loss tracks proportionally with total weight loss has practical implications for how clinicians counsel patients.
How the study worked
Serial body composition measurements were performed on a single patient throughout tirzepatide treatment. This is a case report documenting the time course and magnitude of changes in body weight, fat mass, and skeletal muscle mass. The specific body composition measurement method is not named in the abstract. The authors also reviewed existing literature on muscle loss with GLP-1 receptor agonists.
What this study cannot tell us
This is a single case report (n=1), so the findings may not be generalizable to other patients, ages, body types, or dosing regimens. The patient was 68 years old — younger patients may have different muscle loss patterns. Exercise habits, protein intake, and other lifestyle factors that affect muscle preservation were not described. The specific body composition measurement technique is not detailed in the abstract, and different methods have varying accuracy for muscle mass.
How to read the evidence
This is a single case report — the lowest level of clinical evidence. While it provides uniquely detailed serial body composition data, findings from one patient cannot be generalized. Its value lies in generating a specific, measurable observation that larger studies can test.
When this study was published
Published in 2025, this is very recent and addresses one of the most pressing questions about tirzepatide and GLP-1 drugs. As the first published case with serial body composition measurements on tirzepatide, it fills an immediate gap in the literature.
The bigger picture
The muscle loss question is arguably the most active debate in GLP-1/GIP agonist research right now. As millions of people take tirzepatide (Mounjaro/Zepbound) for weight management, understanding the composition of what they're losing is critical — especially for older adults. This case adds granular data to a discussion that has relied heavily on aggregate trial data. The 34% muscle fraction is consistent with what's been seen in larger studies, but having serial measurements from a single patient helps clinicians visualize the trajectory.
Questions still open
- Would resistance training and increased protein intake during tirzepatide treatment reduce the proportion of weight lost as muscle?
- Does the proportional muscle-to-weight loss ratio hold across different ages, sexes, and starting BMIs?
- At what point does tirzepatide-related muscle loss become clinically dangerous in older adults at risk for sarcopenia?
Common questions
Is it normal to lose muscle on tirzepatide or other GLP-1 drugs?
Can you prevent muscle loss while taking tirzepatide?
Read the original research
Skeletal Muscle Mass and Body Weight Fall Proportionally With Use of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Tirzepatide: Case Report and Review of Literature.
AACE clinical case reports, 11(2), 98-101
Citation
Zinn, Jessica; Poretsky, Leonid. (2025). Skeletal Muscle Mass and Body Weight Fall Proportionally With Use of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Tirzepatide: Case Report and Review of Literature.. AACE clinical case reports, 11(2), 98-101. https://doi.org/10.1016/j.aace.2024.12.001